Patricia Inácio, PhD,  science writer—

Mission Therapeutics and AbbVie have identified several molecules, called deubiquitylating enzymes, or DUBs, that may be potential therapeutic targets to treat Parkinson’s and Alzheimer’s diseases. This comes after the two companies announced a collaboration last year to identify DUB inhibitors to treat these neurodegenerative…

A pilot Phase 2 study evaluating CNM-Au8, an investigational Parkinson’s treatment aiming to protect nerve cells, has started dosing patients, the therapy’s developer, Clene Nanomedicine, announced. The open-label REPAIR-PD (NCT03815916) clinical trial is enrolling up to 24 people, ages 30 to 80 and diagnosed within the past three years,…

RightEye’s Vision System, an advanced eye-tracking device that measures eye tremors to help diagnose Parkinson’s disease at early stages, has been designated a breakthrough device by the U.S. Food and Drug Administration. This FDA designation is given select medical devices or…

Sunovion Pharmaceuticals has re-submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA), once again seeking the approval of its below-the-tongue formulation of apomorphine — called APL-130277 — for Parkinson’s off periods. The re-submission is a follow-up to the FDA’s “complete response…

Inflammation in the gut, a hallmark of autoimmune disorders such as inflammatory bowel disease, may contribute to an earlier risk of developing Parkinson’s disease (PD), according to a recent review of genetic, epidemiological and animal model studies. The risk, however, is very small with only 3% to 5%…

Treatment with Aricept (donepezil) for six weeks does not seem to improve balance, either while standing or walking, for Parkinson’s patients with a minimal history of falls, according to results from a single-site Phase 2 trial. The study, “Effects of augmenting cholinergic neurotransmission on balance in Parkinson’s…

CNM-Au8, an investigational therapy by Clene Nanomedicine, improved the survival of dopaminergic neurons, helped prevent loss of mitochondria, and rescued motor function in a rat model of Parkinson’s disease, a study reports. The effects of CNM-Au8 will now be assessed in an open-label (no placebo group) Phase 2…

Kyowa Kirin’s Nourianz (istradefylline) tablets are now available in the United States as an add-on treatment for off periods in Parkinson’s disease patients on a carbidopa/levodopa regimen. Off periods — when the effects of a medication wear off before a new dose can be taken — are characterized…

Using its brain mapping platform, Inscopix will team up with researchers at the Broad Institute of MIT and Harvard to investigate how changes in brain activity alter the functioning of nerve cells. The goal is to identify new therapeutic targets for Parkinson’s disease. The collaboration will be led…

The Silverstein Foundation for Parkinson’s with GBA together with Q-State Biosciences have launched Chamishi Therapeutics, a company aiming to develop innovative treatments for Parkinson’s disease and other neurodegenerative diseases. Chamishi will initially focus on developing antisense oligonucleotide (ASO) therapies for Parkinson’s patients carrying mutations in the…